

Dan Alexandru Niculescu

EXPERIENȚA PROFESIONALĂ

Șef de Lucrări

Universitatea de Medicină și Farmacie Carol Davila [2020 – În curs]

Localitatea: București

Țara: România

Facultatea de Medicină, Departamentul Clinic 2, Disciplina de Endocrinologie Institutul Național de Endocrinologie C. I. Parhon

Asistent universitar

Universitatea de Medicină și Farmacie Carol Davila [2008 – 2020]

Localitatea: București

Țara: România

Facultatea de Medicină, Departamentul Clinic 2, Disciplina de Endocrinologie Institutul Național de Endocrinologie C. I. Parhon

Preparator universitar

Universitatea de Medicină și Farmacie Carol Davila [2005 – 2008]

Localitatea: București

Țara: România

Facultatea de Medicină, Departamentul Clinic 2, Disciplina de Endocrinologie Institutul Național de Endocrinologie C. I. Parhon

Medic primar endocrinolog

Institutul Național de Endocrinologie C. I. Parhon [2013 – În curs]

Localitatea: București

Țara: România

Secția de Patologie Hipofizară și Neuroendocrină

Medic Specialist Endocrinolog

Institutul Național de Endocrinologie C. I. Parhon [2008 – 2013]

Localitatea: București

Țara: România

Secția de Patologie Hipofizară și Neuroendocrină

Medic rezident endocrinolog
Institutul Național de Endocrinologie C. I. Parhon [2003 – 2007]

Localitatea: București

Țara: România

EDUCAȚIE ȘI FORMARE PROFESIONALĂ

Doctor în Medicină
Universitatea de Medicină și Farmacie Carol Davila [2003 – 2011]

Adresă: București (România)

Rolul GH/IGF-1 și al apneei de somn în producerea rezistenței la insulină și prognosticul diabetului zaharat acromegalic

Medic
Universitatea de Medicină și Farmacie Carol Davila [1996 – 2002]

Adresă: București (România)

Absolvent de Bacalaureat
Colegiul Național "Sfântul Sava" [1992 – 1996]

Adresă: București (România)

COMPETENȚE LINGVISTICE

Limbă(i) maternă(e):

română

engleză

COMPREHENSIUNE ORALĂ: C1 CITIT: C1 SCRIS: B2

EXPRIMARE SCRISĂ: B2 CONVERSAȚIE: B2

COMPETENȚE ORGANIZATORICE

Șef Secție de Patologie Hipofizară și Neuroendocrină, Institutul Național de Endocrinologie C. I. Parhon

Secretar Societatea Română de Endocrinologie 2018-2021

COMPETENȚE LA LOCUL DE MUNCĂ

Ecografie endocrină

Punctie tiroidiană cu ac subțire

Certified Clinical Densitometrist (CCD) – The International Society for Clinical Densitometry

PROIECTE DE CERCETARE

DIRECTOR DE PROIECT

1. **2014 – 2017** Role of serum insulin-like growth factor I (IGF-I) and free fatty acids in insulin resistance, insulin secretion and glucose intolerance of acromegaly – grant UMF “Carol Davila” 28332/04.11.2013, 5 000 EUR; publicații: **Niculescu DA**, Dusceac R, Caragheorghopol A, Popescu N, Poiana C. Disposition Index in Active Acromegaly. *Fron Endocrinol (Lausanne)* 2019, 10: 637; doi: 10.3389/fendo.2019.00637 (factor de impact 3.634).
2. **2007** Insulin resistance – the link between sleep apnea and high blood pressure in acromegaly – grant CNCSIS TD 428/2007, 15 000 EUR; publicații: teza de doctorat "Rolul GH/IGF-1 și al apneei de somn în producerea rezistenței la insulină și prognosticul diabetului zaharat acromegalic" – susținută 11.10.2011

MEMBRU ÎN ECHIPA DE CERCETARE

1. **2015 – 2017** Correlations of bone mineral density with parathyroid function in end-stage renal disease – grant POSDRU/159/1.5/S/135760 CERO – PROFIL DE CARIERĂ: CERCETĂTOR ROMÂN, Contract 5584/5 din 02.03.2015, 5700 EUR; publicații: Dusceac R, **Niculescu DA**, Ismail G, Poiana C. Radius age-adjusted bone mineral density is correlated with parathyroid hormone serum levels in patients with end-stage renal disease. *Acta Endo (Buc)* 2015, 11(2): 175; doi: 10.4183/aeb.2015.175 (factor de impact 0.449).
2. **2012 – 2015** MEDIGENE: Genetic and environmental factors of insulin resistance syndrome and its long-term complications in immigrant Mediterranean populations FP7 contract 279171, 2 996 907 EUR
3. **2007 – 2009** Association case-control study between calpain 10 and insulin resistance in polycystic ovary syndrome – grant CNCSIS A 1333/2007, 30 000 EUR
4. **2007 – 2010** Plasticity of human anterior pituitary cells against resistance to chemotherapy with dopamine agonists in lactotroph pituitary adenomas – grant PNCDI 2 – 41-014/2007

PREMII

International Travel Grant

[2016]

Întâlnirea anuală AACE din Orlando, lucrarea: Niculescu DA, Dusceac R, Galoiu S, Capatina C, Poiana C "Evolution of liver function tests in newly diagnosed, overt hyperthyroidism treated with methimazole" - poster 1207

International Travel Grant

[2010]

Întâlnirea anuală AACE din Boston, lucrarea: Niculescu DA, Gheorghiu ML, Baci I, Stefanescu AM, Badiu C, Poiana C, Radian S, Trifanescu R, Coculescu M "Evaluation of an enzyme immunoassay for plasma and urinary metanephrines in the diagnosis of pheochromocytoma" - poster 106

PUBLICAȚII RELEVANTE

Autor principal

1. **Niculescu DA**, Deacu LG, Caragheorgheopol A, Dusceac R, Procopiuc C, Petris R, Poiana C. Seasonal periodicity of serum parathyroid hormone and its relation with vitamin D in Romania. *Arch Osteoporos* 2020 15(1): 66; doi: 10.1007/s11657-020-00744-1;
2. Dusceac R, **Niculescu DA**, Dobre R, Sorohan MC, Caragheorgheopol A, Tacu C, David C, Poiana C. Bone turnover correlates with bone quantity but not bone microarchitecture in chronic hemodialysis. *J Bone Mineral Metab* 2020, 38(4): 597; doi: 10.1007/s00774-020-01094-1;
3. **Niculescu DA**, Dusceac R, Caragheorgheopol A, Popescu N, Poiana C. Disposition Index in Active Acromegaly. *Fron Endocrinol (Lausanne)* 2019, 10: 637; doi: 10.3389/fendo.2019.00637;
4. Dusceac R, **Niculescu DA**, Dobre R, Dragne MC, Tacu C, Peride I, David C, Checherita I, Poiana C. Chronic hemodialysis is associated with lower trabecular bone score, independent of bone mineral density: a case-control study. *Arch Osteoporos* 2018 13(1): 125; doi: 10.1007/s11657-018-0541-6;
5. **Niculescu DA**, Capatina CAM, Dusceac R, Caragheorgheopol A, Ghemigian A, Poiana C. Seasonal variation of serum vitamin D levels in Romania. *Arch Osteoporos* 2017, 12(1): 113; doi: 10.1007/s11657-017-0407-3;
6. **Niculescu DA**, Baciu IF, Capatina C, Galoiu SA, Gheorghiu ML, Radian S, Trifanescu RA, Caragheorgheopol A, Coculescu M, Poiana C. Acromegaly treatment in Romania. How close are we to disease control? *Endokrynol Pol* 2017, 68(5): 519; doi: 10.5603/EP.a2017.0041;
7. **Niculescu DA**, Dusceac R, Galoiu SA, Capatina CA, Poiana C. Serial Changes of Liver Function Tests Before and During Methimazole Treatment in Thyrotoxic Patients. *Endocr Pract* 2016, 22(8): 974; doi: 10.4158/EP161222.OR;
8. Dusceac R, **Niculescu DA**, Ismail G, Poiana C. Radius age-adjusted bone bineral density is correlated with parathyroid hormone serum levels in patients with end-stage renale disease. *Acta Endo (Buc)* 2015, 11(2): 175; doi: 10.4183/aeb.2015.175;
9. **Niculescu DA**, Ismail G, Poiana C. Plasma Free Metanephrine and Normetanephrine Levels Are Increased in Patients with Chronic Kidney Disease. *Endocrine Practice* 2014, 20(2): 139; doi: 10.4158/EP13251.OR;
10. **Niculescu DA**, Purice M, Coculescu M. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. *Pituitary* 2013, 16(2): 168; doi: 10.1007/s11102-012-0396-6;
11. **Niculescu DA**, Purice M, Lichiardopol R, Coculescu M. Both insulin resistance and insulin secretion are involved in the pre-diabetes of acromegaly. *Acta Endo (Buc)* 2010, 6(1): 35-42, doi: 10.4183/aeb.2010.35;
12. **Niculescu DA**, Purice M, Lichiardopol R, Ciubotaru V, Coculescu M. Short-term impact on glycemic control of partial removal of the tumor mass by transsphenoidal surgery for naive GH-secreting pituitary macroadenomas. *Acta Endo (Buc)* 2008, 4(3): 287; doi: 10.4183/aeb.2008.287;
13. Coculescu M, **Niculescu DA**. Risk of insulin resistance induced by growth hormone. *Acta Endo (Buc)* 2007, 3(4): 461; doi: 10.4183/aeb.2007.461.

Coautor

1. Marinescu MC, Baciu IF, Baculescu N, Capatina C, Dusceac R, Galoiu SA, **Niculescu DA**, Radian S, Trifanescu RA, Baleanu MC, Caragheorgheopol A, Poiana C. Improvement of acromegaly control with multimodal therapy in Romania. *Endokrynol Pol* 2020, 71(3): 235; doi: 10.5603/EP.a2020.0020;
2. Negro R, Attanasio R, Papini E, Guglielmi R, Grimaldi F, Toscano V, **Niculescu DA**, Paun DL, Poiana C. A 2018 Italian and Romanian Survey on Subclinical Hypothyroidism in Pregnancy. *Eur Thyroid J* 2018, 7(6): 294; doi: 10.1159/000490944;
3. Ursu HI, Podia-Igna C, Delia CE, Toma GM, Goran D, Galoiu S, **Niculescu DA**, Giurgiu D, Gheorghiu ML, Anca IA. Iodine status after a decade of universal salt iodization in Romania: a bicentric study in urban areas. *Acta Endo (Buc)* 2014, 10(1): 9; doi: 10.4183/aeb.2014.9;
4. Gheorghiu ML, Hortopan D, Dumitrascu A, Caragheorgheopol A, Stefanescu A, Trifanescu R, **Niculescu DA**, Baciu I, Carsote M, Poiana C, Badiu C, Coculescu M. Age-related endocrine tumors: non-functioning adrenal tumors as compared to pituitary adenomas. *Acta Endo (Buc)* 2009, 5(3): 371; doi: 10.4183/aeb.2009.371;
5. Coculescu M, **Niculescu D**, Lichiardopol R, Purice M. Insulin resistance and insulin secretion in non-diabetic acromegalic patients. *Exp Clin Endocrinol Diabetes* 2007, 115(5): 308; doi: 10.1055/s-2007-961797.

STUDII CLINICE INTERNAȚIONALE

Investigator principal

1. Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant;
2. Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant

Sub-investigator

1. A Phase III, double-blind, randomize, placebo-controlled, parallel-group multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency. **NCT00294619**;
2. A phase III, open-label, uncontrolled, multicenter, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency. **NCT00596037**;
3. A randomized, double-blind, parallel-group, multicenter, multinational study to assess the longterm effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial treatment period of 6 months with rimonabant 20 mg in overweight or obese patients. **NCT00678483**;
4. A Phase IIb study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients with Childhood Onset Growth Hormone Deficiency (GHD). **NCT00778518**;
5. Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients. **NCT00994214**;
6. Open Label Comparative Study Evaluating Efficacy and Safety of Oral Octreolin in Patients with Acromegaly Who are Currently Receiving Parenteral Somatostatin Analogs. **NCT01412424**;
7. A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-Acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering from Adult Growth Hormone Deficiency (AGHD). **NCT01822340**;
8. A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis. **NC T01631214**;
9. A phase IIIb, multicenter, open label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin analogues. **NCT02354508**.

11.12.2020